Abstracts tagged "Biologic agents"

Abstract Number: 2597 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Patient Reported Outcomes in Axial Spondyloarthritis; A Systematic Literature Review and a Call for Action
Santiago Rodrigues Manica^1,2, Joana Leite Silva³, Ana Rita Machado⁴, Constança Coelho⁵, Joana Duarte⁶, Elsa Vieira-Sousa⁷, José Tavares Costa⁸ and Fernando Pimentel-Santos^1,2, ¹CEDOC, NOVA Medical School, Lisbon, Portugal, ²Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ³Serviço de Reumatologia da Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, Ponte de Lima, Portugal, ⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁵Genetics Laboratory, Institute of Environmental Health, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal, ⁶Medical Department, Novartis Pharma, Pharmaceutical products, Oeiras, Portugal, ⁷Rheumatology Department, CAML, Lisbon, Portugal, Lisbon, Portugal, ⁸Rheumatology Department, ULSAM, Ponte de Lima, Portugal, Ponte de Lima, Portugal
Background/Purpose: Patient reported outcomes (PROs) have gained relevance in the evaluation of axial SpA (axSpA), as they convey a more objective patient perspective. The concept…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 1593 • 2018 ACR/ARHP Annual Meeting
Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center
Itziar Calvo Zorrilla¹, Edurne Guerrero Basterretxea¹, Oihane Ibarguengoitia¹, David Montero¹, Maria Luz Garcia Vivar¹, Esther Ruíz Lucea², Ignacio Torre Salaberri², Olaia Begoña Fernandez Berrizbeitia², Juan Maria Blanco Madrigal², Ana Rosa Inchaurbe Pellejero¹, Clara Eugenia Perez Velasquez², Natalia Rivera-García³, Maria Jesus Allande Lopez Linares³, Iñigo Gorostiza-Hormaetxe⁴ and Eva Galíndez Agirregoikoa², ¹Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ⁴Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Spondyloarthritis(SpA) is characterized by axial, peripheral and extra-articular manifestation(EAMs). Its frequency depends on the series, being the psoriasis(Ps), uveitis and inflammatory bowel disease(IBD) the…
Abstract Number: 2611 • 2018 ACR/ARHP Annual Meeting
Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
Sevket Ercan Tunc¹, Ismail Sari¹, Robert D Inman² and Nigil Haroon², ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Lack of efficacy (LOE) to TNF inhibitor (TNFi) treatments is an important issue and can be seen in up to 40% of the patients…
Abstract Number: 6L • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study
Ronald van Vollenhoven¹, Bevra H. Hahn², George C. Tsokos³, Carrie Wagner⁴, Peter Lipsky⁵, Benjamin Hsu⁴, Marc Chevrier⁴, Robert Gordon⁴, Manon Triebel⁶ and Shawn Rose⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Ampel BioSolutions LLC, Charlottesville, VA, ⁶Janssen Biologics Europe, Leiden, Netherlands

Background/Purpose: The IL-12/23 pathway has been implicated in the pathogenesis of SLE. The anti-IL12/23 monoclonal antibody ustekinumab (UST) is efficacious in the treatment of psoriasis,…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 1158 • 2017 ACR/ARHP Annual Meeting
Treatment of Non-Infectious Uveitis: A Comparative Long-Term Study between Biologic Therapy with Adalimumab and Two Conventional Disease-Modifying Antirheumatic Drugs
Esteban Rubio Romero¹, Roberto Aguilar Galán², Raúl Menor Almagro¹, Alejandro Muñoz¹ and Juan Povedano¹, ¹Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ²Ophthalmology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Background/Purpose: Uveitis are inflammatory processes of the vascular layer of the eye, the uvea, which is divided into iris (anterior uvea), ciliary body (intermediate) and…
Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Bente Glintborg¹, Ulf Lindström², Kalle Aaltonen³, Eirik K Kristianslund⁴, Björn Gudbjornsson⁵, Katerina Chatzidionysiou², Johan Askling⁶, Dan Nordström⁷, Merete Lund Hetland⁸, Daniela Di Giuseppe⁹, Lene Dreyer¹⁰, Tanja Schjødt Jørgensen¹¹, Lars Erik Kristensen¹⁰, Kari Eklund³, Gerdur Grondal¹², Sofia Ernestam², Jaana Joensuu³, Tore K Kvien¹³, Elisabeth Lie¹³, Karen M Fagerli¹³, Arni Jon Geirsson¹², Helgi Jonsson¹² and Lennart TH Jacobsson¹⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ³On behalf of the ROB-FIN registry, Helsinki, Finland, ⁴Dept. of Rheumatology, On behalf of the NOR-DMARD registry, Oslo, Norway, ⁵ICEBIO, Reykjavik, Iceland, Reykjavik, Iceland, ⁶Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷ROB-FIN, Helsinki, Finland, Helsinki, Finland, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰On behalf of the DANBIO registry, Copenhagen, Denmark, ¹¹On behalf of the DANBIO registry, Copenhagen F, Denmark, ¹²On behalf of the ICEBIO registry, Reykjavik, Iceland, ¹³On behalf of the NOR-DMARD registry, Oslo, Norway, ¹⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…
Abstract Number: 2409 • 2017 ACR/ARHP Annual Meeting
Older Age and Male Gender Are Independent Predictors of Quantiferon Positivity Among Adult Rheumatic Patients in a Tertiary Care Center from a BCG Vaccinated Country: Hur-BIO Single Center Real Life Results
Emrah Seyhoglu¹, Oguz Abdullah Uyaroglu¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Alper Sari², Omer Karadag², Sule Apras Bilgen², Ali Akdogan², Ihsan Ertenli², Umut Kalyoncu² and Sedat Kiraz², ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: TNF-α inhibitors increase the risk of emergence of active tuberculosis (TB). Screening rheumatic patients for latent TB is a necessity before initiation of biological…
Abstract Number: 475 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona Certain Study
Dimitrios A. Pappas¹, James Murray², Carol J. Etzel¹, David R Nelson², Bernice Gershenson³, Katherine C. Saunders¹, Sabrina Rebello¹ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Massachusetts Medical School, Worcester, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Response to biologic agents approved for RA may be associated with patient reported factors that are not related to disease and usually not included…
Abstract Number: 1425 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Patients with Rheumatoid Arthritis Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry
Philip J Mease¹, Neil Accortt², Mei Liu³, Sabrina Rebello³, Mahdi Gharaibeh² and David Collier², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Amgen Inc., Thousand Oaks, CA, ³Corrona, LLC, Southborough, MA
Background/Purpose: Many treatment options are currently available to patients with rheumatoid arthritis (RA), including tumor necrosis factor inhibitors (TNFi’s). While combination therapy of TNFi’s or…
Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting
Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study
Elena Nikiphorou¹, Désirée van der Heijde², Sam Norton³, Robert B.M. Landewé⁴, Anna Moltó⁵, Maxime Dougados⁶, Filip van Den Bosch⁷ and Sofia Ramiro⁸, ¹LUMC, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Academic Rheumatology, King´s College London, London, United Kingdom, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵Paris Descartes University, Paris, France, ⁶Paris-Descartes University,, Paris, France, ⁷Rheumatology, Ghent University Hospital, Gent, Belgium, ⁸Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…
Abstract Number: 2444 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of CT-P13 in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis: Observational Study in Republic of Korea
Dong-Wook Kim¹, Tae-Hwan Kim², Seong Ryul Kwon³, Eun Young Lee⁴, Chang-Nam Son⁵, Yun Sung Kim⁶, Soung Hun Kim⁷, Yong-Beom Park⁸, Jin-Wuk Hur⁹, Hye-Soon Lee¹⁰, Sang Joon Lee¹¹ and Jee Hye Suh¹², ¹Inje University Busan Paik Hospital, Busan, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Inha University Hospital, Incheon, Korea, Republic of (South), ⁴Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Keimyung University Dongsan Medial Center, Daegu, Korea, Republic of (South), ⁶Chosun University Hospital, Gwangju, Korea, Republic of (South), ⁷Gwangmyeong Saeum Hospital, Gyeonggi-do, Korea, Republic of (South), ⁸Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁹Eulji University Seoul Hospital, Seoul, Korea, Republic of (South), ¹⁰Hanyang University Guri Hospital, Gyeonggi-do, Korea, Republic of (South), ¹¹CELLTRION, Inc., Incheon, Korea, Republic of (South), ¹²CELLTRION.Inc, Incheon, Korea, Republic of (South)
Background/Purpose: CT-P13 is approved as a biosimilar of innovator infliximab for marketing in 81 countries. After approval, observational study has been conducted in Republic of…
Abstract Number: 521 • 2017 ACR/ARHP Annual Meeting
Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis
Mauro Galeazzi¹, Gian Domenico Sebastiani², Jürgen Wollenhaupt³, Jean Dudler⁴, Christof Specker⁵, Reinhard Voll⁶, Pascal Zufferey⁷, Piercarlo Sarzi Puttini⁸, Ombretta Viapiana⁹ and Franziska Bootz¹⁰, ¹Rheumatology, University Hospital of Siena, Siena, Italy, ²Rheumatology, San Camillo Forlanini Hospital, Roma, Italy, ³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁴Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, St. Josef Krankenhaus, Universitätsklinikum Essen, Esssen, Germany, ⁶Clinic for Rheumatology and Clinical Immunology, Medical Center University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁸Rheumatology, Luigi Sacco Hospital, Milan, Italy, ⁹University Hospital Verona, Verona, Italy, ¹⁰Clinical Department, Philochem AG (Philogen Group), Otelfingen, Switzerland
Background/Purpose: The antibody-based targeted pharmacodelivery of cytokines by means of immunocytokines has the potential to enhance therapeutic activity at the site of disease while sparing…
Abstract Number: 1430 • 2017 ACR/ARHP Annual Meeting
Switching from Synthetic to Biologic Dmards – Is There an Insufficient Use of Methotrexate?
Lisa Baganz¹, Adrian Richter¹, Yvette Meißner², Matthias Schneider³, Anke Liebhaber⁴, Ilka Schwarze⁵, Anja Strangfeld⁶ and Angela Zink⁷, ¹German Rheumatism Research Center, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ⁴Rheumatologist, Halle, Germany, Halle, Germany, ⁵Rheumatologist, Leipzig, Germany, Leipzig, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: A recent US-study suggests considerable underuse of MTX and too early switches to biologic (b)DMARDs1 before using a high MTX dose or changing the…

« Previous Page
1
…
3
4
5
6
7
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].